ATE399542T1 - Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel - Google Patents

Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel

Info

Publication number
ATE399542T1
ATE399542T1 AT04765296T AT04765296T ATE399542T1 AT E399542 T1 ATE399542 T1 AT E399542T1 AT 04765296 T AT04765296 T AT 04765296T AT 04765296 T AT04765296 T AT 04765296T AT E399542 T1 ATE399542 T1 AT E399542T1
Authority
AT
Austria
Prior art keywords
alfavbeta6
alfavbeta3
integrin antagonists
antifibrotic agents
antifibrotic
Prior art date
Application number
AT04765296T
Other languages
English (en)
Inventor
Simon Goodman
Detlef Schuppan
Eleonora Patsenker
Yury Popov
Michael Bauer
Matthias Wiesner
Alfred Jonczyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE399542T1 publication Critical patent/ATE399542T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04765296T 2003-10-01 2004-09-16 Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel ATE399542T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03022048 2003-10-01

Publications (1)

Publication Number Publication Date
ATE399542T1 true ATE399542T1 (de) 2008-07-15

Family

ID=34486055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765296T ATE399542T1 (de) 2003-10-01 2004-09-16 Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel

Country Status (18)

Country Link
US (1) US20070117849A1 (de)
EP (1) EP1667668B1 (de)
JP (1) JP4912881B2 (de)
KR (1) KR101191068B1 (de)
CN (1) CN100462068C (de)
AR (1) AR045960A1 (de)
AT (1) ATE399542T1 (de)
AU (1) AU2004283413B2 (de)
BR (1) BRPI0414927A (de)
CA (1) CA2540730C (de)
DE (1) DE602004014795D1 (de)
DK (1) DK1667668T3 (de)
ES (1) ES2308227T3 (de)
MX (1) MXPA06003477A (de)
PL (1) PL1667668T3 (de)
RU (1) RU2388472C2 (de)
WO (1) WO2005039547A1 (de)
ZA (1) ZA200603427B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
US20150086570A1 (en) * 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
IN2015DN00099A (de) 2012-07-18 2015-05-29 Univ Saint Louis
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP3266782B1 (de) 2013-02-07 2019-10-30 SciFluor Life Sciences, Inc. Fluorierte integrin-antagonisten
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP3925959A1 (de) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorierte derivate von 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propansäure und verwendungen davon
HK1244806A1 (zh) 2015-12-30 2018-08-17 Saint Louis University 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
AU2017359028A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
EP3538528B1 (de) * 2016-11-08 2020-12-23 Bristol-Myers Squibb Company Pyrrolamide als alpha-v-integrin-inhibitoren
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
EP3810085A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung der erkrankung des gastrointestinaltraktes mit einem integrin-inhibitor
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
CN118641765B (zh) * 2024-05-17 2025-06-20 中国医学科学院医药生物技术研究所 Tinagl1在制备抗肝纤维化药物中的应用及化合物的新用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
CA2371824A1 (en) * 1999-02-20 2000-08-24 Merck Patent Gesellschaft Mit Beschraenkter Haftung .beta.-alanine derivatives
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
DE10063173A1 (de) * 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AU2002319282B2 (en) * 2001-08-01 2007-06-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
CN1658894A (zh) * 2002-02-14 2005-08-24 默克专利股份有限公司 用于治疗眼病的方法和组合物

Also Published As

Publication number Publication date
AR045960A1 (es) 2005-11-16
KR20060090818A (ko) 2006-08-16
JP4912881B2 (ja) 2012-04-11
BRPI0414927A (pt) 2006-11-07
RU2388472C2 (ru) 2010-05-10
CN100462068C (zh) 2009-02-18
AU2004283413A1 (en) 2005-05-06
ZA200603427B (en) 2007-09-26
JP2007507440A (ja) 2007-03-29
AU2004283413B2 (en) 2010-09-02
ES2308227T3 (es) 2008-12-01
EP1667668B1 (de) 2008-07-02
CA2540730C (en) 2012-08-21
RU2006114395A (ru) 2007-11-27
WO2005039547A1 (en) 2005-05-06
CN1863520A (zh) 2006-11-15
CA2540730A1 (en) 2005-05-06
PL1667668T3 (pl) 2008-10-31
EP1667668A1 (de) 2006-06-14
DE602004014795D1 (de) 2008-08-14
MXPA06003477A (es) 2006-06-05
US20070117849A1 (en) 2007-05-24
KR101191068B1 (ko) 2012-10-15
DK1667668T3 (da) 2008-09-15

Similar Documents

Publication Publication Date Title
DE602004014795D1 (de) Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
DE602005013491D1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
DE602004012891D1 (de) Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
EP1485754A4 (de) Warenanzeigetasche und system
DE602004032276D1 (de) Tetrahydro-Naphthalen und Harnstoffderivate
DE602004020805D1 (de) Weiche und bauschige textilverbundstoffe
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
ATE420084T1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
EP1832272A4 (de) Modifiziertes pulver und dieses verwendende kosmetische zusammensetzung
ATE486091T1 (de) Vegf-fallen und therapeutische verwendungen dafür
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
ATE391531T1 (de) Schweisshemmende mittel
DE60304188D1 (de) Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT
ATE259362T1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel
ATE433448T1 (de) Kondensierte heterocyclen und deren verwendungen
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
EP1551389A4 (de) Dihydroartemisinin und dihydroartemisiten-dimere als mittel gegen krebs und infektionen
DE602004031826D1 (de) Fahrzeugzustandsanalysesystem, fahrzeug und fahrzeugzustandsverwaltungssystem
DE60134575D1 (de) Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator
ATE538093T1 (de) Substituierte 2-carbonylamino-6- piperidinaminopyridine und substituierte 1- carbonylamino-3-piperidinaminobenzole als 5-ht1f- agonisten
DE502004006418D1 (de) Heterocyclyl-substituierte dihydrochinazoline und ihre verwendung als antivirale mittel
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1667668

Country of ref document: EP